Drug Trial Radar · NCT01895972
Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
Last checked: Nov 20, 2026Latest source record: Jul 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Jul 5, 2013
Primary completion
Apr 2, 2015
Study completion Apr 14, 2015
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jul 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
Latanoprostene bunodDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Intraocular PressureTime frame: Baseline and week 4,8,12,16,20,24,28,32,36,40,44,48,52
- Clinical SafetyTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bausch & Lomb Incorporated
Bridgewater, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.